WO2003005991A1 - A core formulation - Google Patents

A core formulation Download PDF

Info

Publication number
WO2003005991A1
WO2003005991A1 PCT/US2001/021676 US0121676W WO03005991A1 WO 2003005991 A1 WO2003005991 A1 WO 2003005991A1 US 0121676 W US0121676 W US 0121676W WO 03005991 A1 WO03005991 A1 WO 03005991A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
glucopyranosyl
patient
core
metformin
Prior art date
Application number
PCT/US2001/021676
Other languages
English (en)
French (fr)
Inventor
Akwete L. Adjei
Yaping Zhu
Anthony J. Cutie
Original Assignee
Aeropharm Technology Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeropharm Technology Incorporated filed Critical Aeropharm Technology Incorporated
Priority to AU2001273310A priority Critical patent/AU2001273310B2/en
Priority to JP2003511799A priority patent/JP2004536841A/ja
Priority to EP01952575A priority patent/EP1429732A4/en
Priority to PCT/US2001/021676 priority patent/WO2003005991A1/en
Priority to MXPA04000176A priority patent/MXPA04000176A/es
Priority to CA002453784A priority patent/CA2453784A1/en
Publication of WO2003005991A1 publication Critical patent/WO2003005991A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • any one of the biguanides i.e. drugs having the action of the stimulation of anaerobic glycolysis
  • these, like metformin increase the sensitivity to insulin in peripheral tissues of the host, e.g. a human being or another animal.
  • These compounds also are involved in the inhibition of glucose absorption from the intestine, suppression of hepatic gluconeogenesis, and inhibition of fatty acid oxidation.
  • Examples of other typical biguanides included in this application are phenformin, buformin etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PCT/US2001/021676 2001-07-10 2001-07-10 A core formulation WO2003005991A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2001273310A AU2001273310B2 (en) 2001-07-10 2001-07-10 A core formulation
JP2003511799A JP2004536841A (ja) 2001-07-10 2001-07-10 コア製剤
EP01952575A EP1429732A4 (en) 2001-07-10 2001-07-10 CORE FORMULATION
PCT/US2001/021676 WO2003005991A1 (en) 2001-07-10 2001-07-10 A core formulation
MXPA04000176A MXPA04000176A (es) 2001-07-10 2001-07-10 Formulacion de nucleo.
CA002453784A CA2453784A1 (en) 2001-07-10 2001-07-10 A core formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/021676 WO2003005991A1 (en) 2001-07-10 2001-07-10 A core formulation

Publications (1)

Publication Number Publication Date
WO2003005991A1 true WO2003005991A1 (en) 2003-01-23

Family

ID=21742691

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021676 WO2003005991A1 (en) 2001-07-10 2001-07-10 A core formulation

Country Status (6)

Country Link
EP (1) EP1429732A4 (ja)
JP (1) JP2004536841A (ja)
AU (1) AU2001273310B2 (ja)
CA (1) CA2453784A1 (ja)
MX (1) MXPA04000176A (ja)
WO (1) WO2003005991A1 (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429747A1 (en) * 2001-07-10 2004-06-23 Kos Life Sciences, Inc. Core formulation comprising pioglitazone hydrochloride and a biguanide
WO2004069229A1 (en) * 2003-02-05 2004-08-19 Ipca Laboratories Limited Dual release anti-diabetic drugs and process of production thereof
AU2001273310B2 (en) * 2001-07-10 2004-10-07 Kos Life Sciences, Inc. A core formulation
WO2004091587A1 (en) * 2003-04-17 2004-10-28 Ipca Laboratories Limited Multiple release anti-diabetic drugs and process of production thereof
WO2005065663A1 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone and metformin formulations
WO2010136847A1 (en) * 2009-05-26 2010-12-02 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Coated metformin with pioglitazone solution
JP2014196314A (ja) * 2003-09-19 2014-10-16 アンドルックス ラボズ リミテッド ライアビリティ カンパニー ビグアニドおよびチアゾリジンジオン誘導体を含む新規の医薬製剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929101A (en) * 1990-02-09 1999-07-27 Pharmacia & Upjohn Company Use of insulin sensitizing agents to treat hypertension
US6191162B1 (en) * 1998-05-28 2001-02-20 Medical Research Institute Method of reducing serum glucose levels

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2001035940A2 (en) * 1999-11-16 2001-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride
US6780432B1 (en) * 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
CA2453775A1 (en) * 2001-07-10 2003-01-23 Kos Life Sciences, Inc. Core formulation comprising pioglitazone hydrochloride and a biguanide
JP2004536841A (ja) * 2001-07-10 2004-12-09 エアロファーム テクノロジー インコーポレイテッド コア製剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5929101A (en) * 1990-02-09 1999-07-27 Pharmacia & Upjohn Company Use of insulin sensitizing agents to treat hypertension
US6191162B1 (en) * 1998-05-28 2001-02-20 Medical Research Institute Method of reducing serum glucose levels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1429732A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1429747A1 (en) * 2001-07-10 2004-06-23 Kos Life Sciences, Inc. Core formulation comprising pioglitazone hydrochloride and a biguanide
AU2001273310B2 (en) * 2001-07-10 2004-10-07 Kos Life Sciences, Inc. A core formulation
EP1429747A4 (en) * 2001-07-10 2005-01-05 Kos Life Sciences Inc CORE FORMULATION WITH PIOGLITAZONE HYDROCHLORIDE AND A BIGUANIDE
WO2004069229A1 (en) * 2003-02-05 2004-08-19 Ipca Laboratories Limited Dual release anti-diabetic drugs and process of production thereof
WO2004091587A1 (en) * 2003-04-17 2004-10-28 Ipca Laboratories Limited Multiple release anti-diabetic drugs and process of production thereof
JP2014196314A (ja) * 2003-09-19 2014-10-16 アンドルックス ラボズ リミテッド ライアビリティ カンパニー ビグアニドおよびチアゾリジンジオン誘導体を含む新規の医薬製剤
WO2005065663A1 (en) * 2003-12-31 2005-07-21 Alpharma, Inc. Rosiglitazone and metformin formulations
WO2010136847A1 (en) * 2009-05-26 2010-12-02 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Coated metformin with pioglitazone solution

Also Published As

Publication number Publication date
CA2453784A1 (en) 2003-01-23
MXPA04000176A (es) 2004-10-27
EP1429732A1 (en) 2004-06-23
JP2004536841A (ja) 2004-12-09
AU2001273310B2 (en) 2004-10-07
EP1429732A4 (en) 2005-01-26

Similar Documents

Publication Publication Date Title
US6524621B2 (en) Core formulation
US6403121B1 (en) Core formulation
US6451342B2 (en) Core formulation comprised of troglitazone and a biguanide
US6780432B1 (en) Core formulation
US6296874B1 (en) Core formulation comprising troglitazone and abiguanide
CA2470581C (en) Antidiabetic formulation and method
US20060141023A1 (en) Pharmaceutical compositions containing abiguanide-glitazone combination
IL158506A (en) Pharmaceutical dosage form for oral administration once daily that combines metformin and at least one other anti-diabetic active ingredient
US6461639B2 (en) Core formulation
AU2001273310B2 (en) A core formulation
AU2001273289B2 (en) Core formulation comprising pioglitazone hydrochloride and a biguanide
AU2001273310A1 (en) A core formulation
AU2001257456B2 (en) A core formulation
AU2001273289A1 (en) Core formulation comprising pioglitazone hydrochloride and a biguanide
AU2001257456A1 (en) A core formulation
AU2001273290B2 (en) Core formulation comprising troglitazone and a biguanide
AU2001273290A1 (en) Core formulation comprising troglitazone and a biguanide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/000176

Country of ref document: MX

Ref document number: 2453784

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001952575

Country of ref document: EP

Ref document number: 2003511799

Country of ref document: JP

Ref document number: 2001273310

Country of ref document: AU

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001952575

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001273310

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2001952575

Country of ref document: EP